Pharmacokinetics of Netilmicin in the Presence of Normal or Impaired Renal Function
Overview
Authors
Affiliations
A pharmacokinetic study of netilmicin was conducted in 12 healthy subjects and 24 subjects with chronic renal failure. After intramuscular administrations of 2 and 3 mg of netilmicin per kg in normal subjects, the mean peak serum concentrations were 5.46 and 8.83 mug/ml, respectively. After intravenous infusions of identical doses, the mean maximum serum levels, occurring at the end of the infusion, were 11.79 and 15.75 mug/ml, respectively. The pharmacokinetic data were very similar via the two routes of administration and for the two doses. The elimination half-life was 2.20 h, and 80 to 90% of the injected dose was recovered in urine during the first 24 h. After intramuscular administration of 2 mg/kg in subjects with chronic renal impairment, the elimination half-life increased to 29.48 h, and urinary elimination was inversely related to the degree of impairment. A study was conducted throughout hemodialysis sessions: serum concentrations decreased by 63.3%. The linear relationships between the elimination rate constant and creatinine clearance and the elimination half-life and serum creatinine allowed us to establish dosage schedules according to the degree of renal failure.
Jiao Y, Moya B, Chen M, Zavascki A, Tsai H, Tao X Antimicrob Agents Chemother. 2019; 63(7).
PMID: 30988147 PMC: 6591590. DOI: 10.1128/AAC.00425-19.
Yeh E, Brown G Can J Hosp Pharm. 2012; 62(6):457-63.
PMID: 22478933 PMC: 2827012. DOI: 10.4212/cjhp.v62i6.843.
Population pharmacokinetics of netilmicin in short-term prophylactic treatment.
Jauregizar N, Wald J, Astobieta A, Rodriguez Sasiain J, Lukas J, Calvo R Br J Clin Pharmacol. 2003; 55(6):552-9.
PMID: 12814449 PMC: 1884271. DOI: 10.1046/j.1365-2125.2003.01783.x.
Pharmacokinetics and metabolism of 14C-isepamicin in humans following intravenous administration.
Lin C, Korduba C, Affrime M, Radwanski E, Nomeir A, Batra V Antimicrob Agents Chemother. 1995; 39(10):2201-3.
PMID: 8619567 PMC: 162914. DOI: 10.1128/AAC.39.10.2201.
Keller F, Erdmann K, Giehl M, Buettner P Clin Pharmacokinet. 1993; 25(1):71-9.
PMID: 8354018 DOI: 10.2165/00003088-199325010-00005.